Introduction: Congenital factor XIII (FXIII) deficiency is a rare, autosomal recessive bleeding disorder usually caused by mutations in the F13A1 gene that produce a severe quantitative (type I) deficiency of the FXIII-A subunit. Aim: To determine the genotypes of patients with severe FXIII-A deficiency treated with recombinant FXIII-A subunit (rFXIII-A 2 ) participating in three international efficacy and safety trials. Methods: We determined the genotypes of 73 patients in total; 32 had already undergone genotype analysis and were known to carry F13A1 mutations that have been previously reported in the literature. Mutation screening was performed in 41 patients with unknown genetic status using direct sequencing. Results: In total, 51 distinct mutations in 73 patients were identified. Two patients showed a phenotype of severe FXIII-A deficiency, despite having heterozygous missense mutations. Two siblings carried a missense mutation in the F13A1 gene (p.Ser296Arg) in combination with a novel, probably polymorphic variant of the F13B gene (p.Ser654Phe). Molecular modelling of five F13A1 novel missense mutations (p.Leu171Phe, p.Glu204Lys, p.Leu276Phe, p.Asp405His and p.Gly411Cys) predicted a damaging effect of these mutations on protein structure. Although five patients treated with rFXIII-A 2 had transient, low-titre, non-neutralizing anti-rFXIII antibodies, no patients developed FXIII-neutralizing antibodies (inhibitors). Conclusion: The identified mutations are causally implicated in severe FXIII deficiency; however, they do not appear to increase the risk of neutralizing antibody development against rFXIII-A 2 .
Introduction
Congenital factor XIII (FXIII) deficiency is a rare, autosomal recessive bleeding disorder affecting 1 in 1-3 million people [1, 2] . The disorder was first described in 1960 by Duckert et al. [3] . Superficial bruising and subcutaneous and muscular haematomas are among the most common bleeding sites, whereas intracranial bleeding is the leading cause of death. Impaired wound healing and spontaneous abortions in females feature frequently [4, 5] .
Based on genotype, there are two types of FXIII deficiency. The most common is FXIII-A subunit deficiency, caused by mutations in the F13A1 gene (chromosome 6, p24-25 [6] ). FXIII-B subunit deficiency is caused by underlying mutations in the F13B gene (chromosome 1, q32-32.1 [7] ) and accounts for <5% of cases [8] . Both types result in the absence of FXIII catalytic activity in plasma [9] . Combined FXIII-A and FXIII-B deficiency is rarely reported. The molecular defects responsible for FXIII deficiency are listed in the Human Gene Mutation Database (http://www.b iobase-international.com) and FXIII mutation database (http://www.f13-database.de) [8] . Most (>99%) patients with FXIII-A deficiency have a quantitative deficiency (FXIII-A type 1 deficiency); qualitative (FXIII-A type 2) deficiencies account for <1% of cases (personal observation).
In plasma, FXIII proenzyme circulates as an A 2 B 2 heterotetramer (pFXIII-A 2 B 2 ) composed of two catalytic A subunits bound to two carrier B subunits [10] . Intracellular FXIII exists as a homodimer of two A subunits (cFXIII-A 2 ) [10] . The A subunit contains 730 amino acids and includes an activation peptide and four distinct domains [11, 12] , whereas the B subunit consists of 10 tandem repeats (641 amino acids) [13] . Activated FXIII-A subunits promote clot stability by forming covalent (e-[c-glutamyl] lysine) bonds between fibrin monomers and cross-linking fibrin with other proteins [4] .
This study compares mutations within the F13A1 and F13B genes of patients enrolled in three international trials in the mentor TM clinical programme ( In panel a, the left and right images each show the structure of the wild-type FXIII-A subunit and the mutated form carrying the mutation p.Leu171Phe. The backbone is represented as a ribbon with colour assigned according to secondary structure. The mutated and wild-type residues, along with other neighbouring residues of interest (i.e. thrombin cleavage site residues and p.Phe45), are depicted in stick format. Panel b shows the structural alignment of the local secondary structures from the core domain of the zymogenic and activated forms of the FXIII-A subunit. The backbone is shown as a ribbon, where green represents the activated form and yellow represents the zymogenic form. The mutated and wild-type residues, along with other neighbouring residues of interest (i.e. p.Lys468 and p.Gly471 residues), are depicted in stick format. Hydrogen bonds are depicted as prominent black dotted lines. In panel c, the left and right images each show a close-up structural view of the wild-type FXIII-A subunit and the mutated form carrying the mutation p.Leu276Phe. The backbone is represented as a ribbon, with colour assigned according to secondary structure. The mutated and wild-type residues, along with other neighbouring residues of interest (i.e. the catalytic cysteine p.Cys315 and p.Phe318 residues), are depicted in stick format. Calcium bound to calcium-binding pockets is shown as yellow balls. Hydrogen bonds are depicted as prominent black dotted lines. Panel d shows the structure of the dimeric interface, as observed in the zymogenic form of the FXIII-A subunit. The central dotted line is a line of symmetry for the two dimeric halves. The backbone is shown as a grey ribbon with green portions representing specific interface regions. The mutated and wild-type residues, along with other neighbouring residues of interest (i.e. the p.Arg261 and p.Cys410 residues) are depicted as blue sticks. [Colour figure can be viewed at wileyonlinelibrary.com] been described in detail [14] . In all three trials, patients were dosed with 35 IU˙kg À1 rFXIII-A 2 every 28 days. Patients comprised 41 subjects enrolled in F13CD-1725 (23 centres), 26 subjects enrolled in F13CD-3720 (18 centres) and 6 subjects enrolled in F13CD-3760 (5 centres). Patients were from Europe (n = 32), North America (n = 23), Israel (n = 13) and Japan (n = 5) ( Table 1) . Most patients (63%) were adults.
Materials and methods

Subjects
Immunogenicity was assessed using an anti-rFXIII antibody enzyme-linked immunosorbent assay and an in vitro neutralizing antibody assay to confirm and characterize anti-rFXIII antibodies [15] . All patients receiving rFXIII-A 2 were monitored for the development of FXIII antibodies before administration of rFXIII-A 2 , at scheduled visits to the hospital, as well as during any unscheduled visits.
Of the 73 patients, 32 (44%) had already undergone genotype analysis and were known to carry F13A1 mutations, as reported in the literature prior to initiation of the rFXIII-A 2 trials. Mutation screening was performed in the remaining 41 (56%) patients, who had unknown genetic status. Direct deoxyribonucleic acid (DNA) sequencing confirmed the diagnosis of FXIII-A deficiency.
Polymerase chain reaction and sequencing
Genomic DNA was prepared from lymphocytes derived from EDTA-treated whole blood using standard procedures [16] and amplified by polymerase chain reaction (PCR) using primers [17] . Exceptions to this were primers for exon 9 (F13A-Ex9 F-
, which were designed by the Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/prime r3.cgi/). The F13B gene was amplified using primers described by Iva skevi cius et al. [9] . PCR amplicons were sequenced using an ABI Prism 3130TL (Applied Biosystems, Weiterstadt, Germany).
In silico/structural analysis of F13A1 missense mutations
The structure of novel missense mutations was analysed as described by Biswas et al. [18] . Crystallographic models of recombinant human cellular FXIII-A (cFXIII-A) zymogen (EC: 2.3.2.13, solved to 2.1 A resolution) and activated calcium-bound human cFXIII-A (solved to 1.98 A resolution) were downloaded from the Protein Data Bank (PDB; data files 1F13 and 4KTY, respectively) [19, 20] . These crystallographic models were viewed, analysed and graphically rendered using YASARA software (version 13.3.26, YASARA Biosciences GmbH, Vienna, Austria) [21] . Each downloaded PDB file was optimized by a very short solvated molecular dynamic simulation run of 500 ps using the Amber03 force field. The average structure derived from simulation was used for further structural analysis. Wild-type residues were replaced with specific mutant residues in the respective FXIII PDB files and optimized for best possible rotamer. The local environment of the wild-type and mutant residues was inspected to make a comparative assessment. Hydrogen bonds and potential clashes within the high-resolution structures were detected using the standard visualization option of YASARA. 
Results
Mutational spectrum
All patients carried mutations within the F13A1 gene (Table 1) , resulting in FXIII-A subunit deficiency; none had causative mutations in the F13B gene. All patients were thus eligible to receive treatment with rFXIII-A 2 .
In total, 51 distinct F13A1 gene mutations were identified, comprising 23 missense mutations (Table 2) , nine small deletions, seven splice-site mutations, six nonsense mutations, three small insertions, two large deletions and one large duplication (Table 3) . Forty-nine (67%) patients were homozygous for causative mutations and 22 (30%) were expected to be compound heterozygous. In the remaining two (3%) patients, only one heterozygous mutation was identified in the F13A1 gene, despite both patients having severe FXIII-A deficiency. We assume the remaining, unidentified mutation could not be detected within the parameters of our screening procedures.
Common mutations
The IVS5-1G>A (c.691-1G>A) mutation was the most common gene defect, occurring in homozygous or heterozygous form in 13/73 (18%) patients from the USA (n = 4), Germany (n = 3), Finland (n = 2), Switzerland (n = 2), Austria (n = 1) and France (n = 1).
Seven of 13 patients from Israel (Palestinian Arabs) carried the p.Leu661Pro mutation. This mutation is found in the healthy Arab population at a minor allele frequency of 0.0033 [24] . In addition, 5/73 (7%) patients from the USA (n = 3) and Spain (n = 2) carried a missense mutation in exon 3 (p.Arg78His, c.233G>A). All other distinct mutations identified occurred in three or fewer patients (Tables 2 and 3 ).
Novel mutations
Among 51 distinct mutations identified in this cohort, 17 were previously unreported in the literature. These novel mutations comprised five missense mutations, six small deletions, three nonsense mutations, two splice-site defects and one large deletion.
Missense mutations
Of five novel missense mutations identified, four were located in the central core domain of FXIII-A, and one was within the b-sandwich domain. All these mutations occurred in highly conserved regions of the FXIII-A molecule as compared with other transglutaminases [25] . The p.Leu171Phe (c.511C>T) mutation was found in heterozygous form in one patient (from Spain). This mutation is located within the b-sandwich domain and forms part of an antiparallel b sheet that continues into an inner loop, surrounded by an outer loop containing the thrombin cleavage site.
Another novel missense mutation, p.Glu204Lys (c.610G>A), was detected in heterozygous form in male identical twins from Germany. This mutation is located in a short helix within the core domain. This helix remains structurally unchanged upon activation (i.e. there is no difference between the activated and zymogenic forms). The p.Glu204 residue appears to play a crucial role in structural consistency, as it forms domain-stabilizing hydrogen bonds with a backbone of p.Gly471 and side chain of p.Lys468. These hydrogen bonds appear to stabilize the ends of the region within the core domain that contains the antiparallel b sheet (p.463-p.477), which would otherwise be unstable.
The p.Leu276Phe (c.826C>T) mutation was found in heterozygous form in one patient from Spain. This mutation is located within a b strand in the core domain, directly below the hydrophobic pocket that carries the catalytic p.Cys315 residue.
Two further novel missense mutations (p.Asp405His, c.1213G>C and p.Gly411Cys, c.1231G>T) were identified in heterozygous form in one patient from France and USA, respectively. These mutations were close to the catalytic triad of the FXIII-A subunit. The p.Asp405 residue is located on the dimeric interface of the FXIII-A 2 dimer, stabilizing it by forming hydrogen bonds with a positively charged p.Arg261 residue from the opposite monomer. The p.Gly411 residue is also proximal to this dimeric interface, although not directly functioning as part of it. In the zymogenic form of the FXIII-A subunit, the residue occurs at the end of a very short beta strand in the middle of a fairly extended flexible loop, which is stabilized by interaction with the opposite monomer (p.Asp405-p.Arg261).
Small deletions
Similar to the novel missense mutations detected, all deletions identified were private mutations. The most proximal heterozygous frameshift deletion was in exon 5 (c.617-625delTCCTGAATG). This 9-bp deletion causes deletion of three amino acids (p.207Val-p.208Leu-p.209Asn). A heterozygous 6-bp deletion within the intron 7/exon 8 junction (IVS7-1_-3del-TAG [c.974-1_-3delTAG] and c.974-976delTTT) was identified in one patient from the USA; this rare deletion may predict a splicing error.
Two other novel heterozygous frameshift deletions in exon 11 (c.1443-1446delTTAC) and exon 13 (c1823-1824delTT) were identified in another male patient from the USA. Due to the frameshift, both mutations result in premature termination of the protein at amino acid positions 495 and 614.
A homozygous frameshift deletion identified in a patient from Germany (c.1475-1476delGA) was located in exon 12, within three GA repeats (GAG-AGA) in [40] codons at amino acid positions 491 and 492. Deletion of two nucleotides would result in premature termination of the sequence at amino acid position 503. Finally, two siblings from Canada were compound heterozygous for a previously described missense mutation (p.Arg261His) and 1-bp deletion in exon 14 (c.2044delC ). This frameshift deletion in the terminal part of the F13A1 gene results in premature termination of the protein at amino acid position 706.
Nonsense mutations
All three novel nonsense mutations identified (p.Arg79X, p.Gly115X and p.Tyr168X) were located in the b-sandwich domain. Each mutation would result in complete absence of the catalytic core domain and both barrel domains.
Splice-site mutations
Both novel splice-site mutations were found in the splice donor site of introns 3 and 12 (IVS3 + 1G>A [c.319 + 1G>A] and IVS12 + 1G>A [c.1747 + 1G>A]). Both defects are predicted to result in splicing errors.
Large deletion
One patient from the USA was believed to have a large novel deletion with an estimated size of >30 kb involving exons 11, 12, 13 and 14 of the F13A1 gene. However, this could not be definitively confirmed, as sequencing of the PCR product failed.
Mutation type and antibodies
Five (6.8%) patients previously treated with plasmaderived FXIII concentrates prior to rFXIII-A 2 developed transient, low-titre anti-rFXIII antibodies that had no neutralizing activity. In four patients aged 8, 8, 14 and 16 years (from mentor TM 1), the FXIII-binding antibodies occurred after the first (n = 3) or second exposure to rFXIII-A 2 (n = 1). In two of the patients, the antibodies disappeared while the patient was still receiving rFXIII-A 2 (after 1 and 4 months, respectively). One of these patients returned to his previous prophylactic treatment (the plasma-derived FXIII concentrate Fibrogammin â ) and the other patient continued to receive rFXIII-A 2 . In two patients, the rFXIII antibodies disappeared after 4 and 8 months, and the patients resumed their local standard treatment of monthly replacement with FXIII-containing product (cryoprecipitate) after their second dose of rFXIII-A 2 . The fifth patient (a 6-yearold from mentor TM 6) developed rFXIII-binding antibodies after 3.5 years of treatment with rFXIII-A 2 . The FXIII antibodies disappeared after 2 months, and the patient continued prophylaxis with rFXIII-A 2 . In all cases, the non-neutralizing antibodies were found to be of no clinical significance, and no dose adjustments were made.
Interestingly, two patients (one male and one female) who developed non-neutralizing antibodies were siblings from the USA carrying the same common, homozygous splice-site mutation in intron 5 (IVS5-1 G>A). A third patient (from Canada) carried two heterozygous missense mutations (p.Gln230Arg; pSer414Leu). The fourth patient with non-neutralizing anti-rFXIII antibodies was from Spain, and was also heterozygous for two missense mutations (p.Arg78His; p.Leu276Phe). The remaining patient with a transient, non-neutralizing antibody was a child from the USA who carried a missense mutation (p.Gly411Cys) and small deletion (c.1711-1713delAAG).
Normal variations in the F13A1 and F13B genes F13a1. A heterozygous variant at p.Thr577Met was found in a patient from the USA who was also compound heterozygous for two previously described causative mutations in exon 3 and intron 5. This variant, located in the barrel 1 domain, is a rare polymorphism with a minor allele frequency of 0.001 in the normal population (http://www.ncbi.nlm.nih. gov).
One patient from Spain with a heterozygous missense mutation in exon 3 was also heterozygous for a candidate polymorphism at p.Leu589Gln in exon 13. The p.Leu589Gln polymorphism is located on the surface of the barrel 1 domain and appears not to significantly alter local structure, as it does not affect interaction with neighbouring amino acids. However, it is possible that the polymorphism might influence interactions with the FXIII-B subunit. As with the p.Thr577Met variant, the p.Leu589Gln variant is a rare polymorphism with a minor allele frequency of 0.001 (http://www.ncbi.nlm.nih.gov).
F13b. Two siblings of Pakistani origin from the UK carried a missense mutation in the F13A1 gene (p.Ser296Arg) and a novel variant in the F13B gene (p.Ser654Phe). This variant does not seem to significantly affect B-subunit stability, as it is located in the terminal part of the molecule. In addition, no reductions in the half-life of infused rFXIII-A 2 have been observed in these patients [15] .
Discussion
This study, which compared mutations in patients with severe FXIII congenital deficiency from Europe, North America, Israel and Japan, is the largest international study to date. FXIII-A subunit deficiency was confirmed in all patients by genotyping prior to initiating treatment with rFXIII-A 2 . Mutation screening by direct sequencing, performed in patients with unknown genetic status, was completed no later than 4 weeks after receipt of blood samples. With an overall sensitivity of 95%, this screening procedure was highly sensitive and reliable for screening mutations in the F13A1 gene. The only disadvantage of this method is its inability to identify heterozygous large deletions and duplications; these, however, are underrepresented in the F13A1 gene, and have previously been detected in <5% of patients with FXIII-A subunit deficiency [8] . Similarly, our study found large deletions and duplications in only 3/73 (4%) patients. Recently, Nugent et al. [26] established a Next Generation Sequencing (NGS) panel for screening the F13A1 and F13B genes, which can detect large deletions as well as other mutations. The NGS assay may therefore provide an alternative to traditional sequencing.
Similar to previously published studies [8] , we found a high incidence of splice-site mutations in intron 5. This can be explained, in part, because most patients were recruited from Europe or the USA, which historically has a high number of European immigrants. The splice-site mutation IVS5-1G>A was not found in patients from Japan or Israel, suggesting this mutation may be underrepresented in Asian, Jewish and Arab populations.
Five novel missense mutations were identified. When tested on two mutation prediction tools/servers (SIFT and Polyphen2) all except p.Leu171Phe were predicted to be deleterious to FXIII protein function. The p.Asp405His mutation was also predicted to be safely tolerated when tested by the SIFT tool, but to be damaging when Polyphen2 was used.
Structural analysis of the five novel missense mutations, using crystallographic models of the zymogenic and activated forms of FXIII, predicted putative functional implications for the protein (Fig. 2) . With regard to the p.Leu171Phe mutation, the substitution of an aliphatic amino acid Leu by an aromatic amino acid Phe in this b-sheeted region would normally be tolerated, as residues like Leu, Ile, Val and Phe are found in most b-sheet-bearing domains. However, introduction of a large aromatic residue in the outer loop (which contains the thrombin cleavage site) might create steric hindrance with a proximal p.Phe45 residue and could thus alter the cleavage dynamics of the loop, even though the aromatic residue itself does not directly interact with the cleavage site participant residues. Therefore, the p.Leu171Phe mutation might indirectly affect thrombin cleavage and activation of FXIII.
The mutation p.Glu204Lys (i.e. substitution of an acidic, negatively charged Glu residue for a basic, positively charged Lys residue) in the core domain negates the domain-stabilizing effect of the Glu residue by breaking its hydrogen bonds with p.Lys468 and p.Gly471. This, in turn, leads either to a misfolded zymogenic protein or an unstable core domain that tends to destabilize during the conformational changes occurring during FXIII activation.
The mutation p.Leu276Phe (i.e. substitution of a small, non-aromatic Leu residue for a large aromatic Phe residue) in the core domain would create steric problems with a proximal p.Phe318 residue that forms part of the helix ending in the catalytic residue p.Cys315. This steric interference is likely to disturb the catalytic pocket of FXIII-A, thereby influencing its efficiency. Interestingly, the p.Leu276 residue is also proximal to a constitutively bound calcium-binding pocket. Consequently, the disturbance created by the p.Leu276Phe mutation might also alter the ability of this binding pocket to capture calcium, which, in turn, could change the calcium conformational dynamics of FXIII-A.
The mutation Asp405His (i.e. substitution of a negatively charged Asp residue for an aromatic His residue) contributes to the breaking of hydrogen bonds with p.Arg261 from the opposite monomer. However, depending on the protonation state of the mutated His residue, compensatory or overcompensatory cation-pi interactions with the p.Arg261 residue may occur. In any case, substitution of an Asp residue for a His residue at this dimeric interface will certainly affect (positively or negatively) the association dynamics of the dimeric molecule.
The mutation p.Gly411Cys (i.e. substitution of a Cys residue) in the core domain may have interesting implications, especially as there is a Cys residue immediately adjacent (p.Cys410). This means that the p.Gly411Cys mutation may cause the formation of vicinal disulphide bonds during protein folding. A vicinal disulphide bond usually results in a tight, constrained turn within protein structures; this kind of rigid turn might alter the dimeric interface and destabilize the FXIII-A subunit dimer.
Although five patients developed transient, non-neutralizing, low-titre anti-rFXIII antibodies, no patients treated with rFXIII-A 2 developed neutralizing FXIII antibodies over a total follow-up time of 248 personyears. The overall incidence of neutralizing antibodies in patients with congenital FXIII deficiency remains unknown, but is expected to be much lower than for other coagulopathies (e.g. haemophilia). In addition, there is no known correlation between mutation type in the FXIII gene and antibody development. Nevertheless, it might be speculated that carriers of missense mutations have a lower risk of developing antibodies than carriers of null mutations (nonsense mutations, small and large deletions and insertions or splice-site mutations), which, in most cases, predict non-measureable FXIII activity. In our study, 40/73 (55%) patients carried homozygous or heterozygous missense mutations that might reduce the possibility of developing an inhibitor. Furthermore, only 3/73 (4%) patients had large F13A1 rearrangements, which predict highest risk of inhibitor development. To our current knowledge, the genetic predispositions associated with inhibitor development seen in haemophilia A and B [27] are not associated with FXIII deficiency. Further investigation and collection of real-world data on FXIII deficiency are warranted.
In conclusion, all patients with severe FXIII-A deficiency receiving treatment with rFXIII-A 2 in three international trials showed mutations in the F13A1 gene and no mutations in the F13B gene. Contributing to the literature, a number of novel mutations in the F13A1 gene associated with severe FXIII-A deficiency was identified. As no inhibitors were seen in patients exposed to regular prophylaxis with rFXIII-A 2 , no association between the molecular defects identified in this study and the development of neutralizing antibodies towards rFXIII-A 2 could be identified.
